Want to see JP:4583 full AI Analyst Report?
Chiome Bioscience Inc. (4583) AI Stock Analysis
Chiome Bioscience Inc.
(TSE/TYO:4583)
The overall score of 46 is heavily weighed down by the company's poor financial performance, including declining revenues, persistent unprofitability, and significant cash burn. A lack of traditional valuation support further suppresses the rating. However, the score is slightly lifted by moderately bullish short-to-medium-term technical momentum, as the stock trades above key moving averages despite its long-term downtrend.
Chiome Bioscience Inc. (4583) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.22B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.56M
- Price to Earnings (P/E)
- -6.6
- Beta (1Y)
- 0.58
- Revenue Growth
- -19.99%
- EPS Growth
- 16.36%
- Country
- Japan
- Employees
- 49
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Chiome Bioscience Inc. Business Overview & Revenue Model
Company Description
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology f...
How the Company Makes Money
Publicly available, company-specific details on Chiome Bioscience Inc.’s current revenue model and the breakdown of its revenue streams (e.g., product sales vs. licensing, collaboration milestones, research funding, or royalties), as well as signific...
Chiome Bioscience Inc. Financial Statement Overview
Summary
The company faces significant fundamental risks. Despite a conservative debt-to-equity ratio of 0.23, severe unprofitability, a 23% revenue contraction, and critical cash burn levels threaten long-term operational sustainability.
Income Statement
25NegativeBalance Sheet
42NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 615.15M | 593.29M | 780.81M | 682.46M | 630.82M | 480.85M |
| Gross Profit | 375.24M | 355.58M | 432.02M | 397.72M | 347.78M | 242.81M |
| EBITDA | -910.50M | -972.64M | -1.01B | -1.21B | -1.24B | -1.28B |
| Net Income | -925.73M | -982.78M | -1.02B | -1.22B | -1.24B | -1.29B |
Balance Sheet | ||||||
| Total Assets | 1.91B | 1.73B | 2.47B | 1.75B | 2.22B | 3.49B |
| Cash, Cash Equivalents and Short-Term Investments | 1.37B | 1.21B | 2.06B | 1.33B | 1.73B | 2.69B |
| Total Debt | 67.50M | 261.70M | 281.50M | 291.00M | 184.00M | 180.00M |
| Total Liabilities | 341.26M | 605.44M | 548.55M | 593.73M | 424.72M | 384.58M |
| Stockholders Equity | 1.57B | 1.12B | 1.92B | 1.16B | 1.79B | 3.11B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -976.07M | -1.00B | 0 | -1.19B | 0 |
| Operating Cash Flow | 0 | -935.99M | -1.00B | -1.07B | -1.19B | -1.36B |
| Investing Cash Flow | 0 | -55.46M | 0 | 173.00K | 0 | -3.52M |
| Financing Cash Flow | 0 | 133.20M | 1.74B | 667.30M | 1.13B | 1.94B |
Chiome Bioscience Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Negative. The current price of 86.00 is below the 20-day moving average (MA) of 93.40, below the 50-day MA of 92.56, and below the 200-day MA of 93.37, indicating a bearish trend. The MACD of -0.84 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4583.
Chiome Bioscience Inc. Peers Comparison
Overall Rating
JP:457078Outperform
JP:456563Neutral
JP:457960Neutral
JP:458855Neutral- JP:458346Neutral
JP:458741.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4570 | 78Outperform | JPY 9.56B | 25.52 | ― | 0.59% | 13.46% | 42.41% |
| JP:4565 | 63Neutral | JPY 133.37B | -26.50 | -8.51% | ― | 23.72% | 12.48% |
| JP:4579 | 60Neutral | JPY 16.61B | 69.05 | ― | ― | 20.64% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4588 | 55Neutral | JPY 223.32B | -143.92 | ― | ― | 1662.38% | 42.86% |
| JP:4583 | 46Neutral | JPY 7.29B | -6.56 | ― | ― | -19.99% | 16.36% |
| JP:4587 | 42Neutral | JPY 145.02B | -39.81 | -7.17% | ― | 0.62% | 27.66% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4583 | Chiome Bioscience Inc. | 86.00 | -42.00 | -32.81% | |
| JP:4587 | Peptidream | 1119.00 | -412.00 | -26.91% | |
| JP:4565 | Sosei Group Corporation | 1585.00 | 782.00 | 97.38% | |
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 1009.00 | 538.02 | 114.23% | |
| JP:4579 | RaQualia Pharma Inc. | 618.00 | 90.00 | 17.05% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7910.00 | 7145.00 | 933.99% |
Chiome Bioscience Inc. Corporate Events
Chiome Bioscience Outlines Q2 FY2026 Results and R&D Focus
Chiome Bioscience has released supplementary information for its second-quarter fiscal 2026 results, outlining financial performance and operational highlights for the period. The materials also reference updates to the company’s therapeutic an...
Chiome Bioscience Narrows Losses as Sales Rise and Balance Sheet Strengthens
Chiome Bioscience reported non-consolidated net sales of ¥273 million for the six months ended June 30, 2026, an 8.7% increase year on year, while narrowing its net loss to ¥483 million as operating and ordinary losses also improved. Total...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 10, 2026